BRCA1 and neoplasm: Lastly, Moiseyenko et al. showed that GC patients with tumor tissue samples that had low BRCA1 transcript levels had a significantly higher overall response and clinical benefit compared to those with high BRCA1 transcript levels when administered a combination of platinum-based agents, fluoropyrimidines, and anthracyclines [37].